ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma, Commits to $20 Million Investment

ABVC BioPharma, Inc. has converted a $100,000 convertible note into 10,000 shares of AiBtl BioPharma Inc. common stock at $10 per share, based on an independent valuation, and plans to invest up to $20 million in AiBtl, reinforcing its position as a lead strategic investor. This investment is expected to help AiBtl meet licensing obligations and accelerate Phase III development of its CNS drug candidates, ABV-1504 and ABV-1505, under a licensing agreement that includes equity, milestone payments, and royalties.

Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the company's commitment to AiBtl's success, highlighting the potential for future milestone and royalty revenues. AiBtl, focusing on CNS disorders with botanical-based candidates, aims to advance its pipeline with this investment, particularly in Asia-Pacific markets, through collaborations with global pharmaceutical partners.